Τhe restless spirit of Mr. D. Pentafragas, a pharmacist originating from Evros, led him to the creation of a "Greek Pharmaceutical Industry of European Standards", one that was to become a well-deserved representative of the Greek drug abroad. With limited resources, yet with numerous dreams, he set the basis for the production of branded Greek drugs, thereby offering significant contributions to the national economy, the healthcare community, and his fellow-men.
For 50 years, ELPEN has been steadily investing in research, paving the way for innovative drugs of high quality and therapeutic value. The creation of the largest Research & Experimental laboratory in our country promotes, in an exemplary manner, the creative collaboration between the public and private sector. Over nineteen years, ELPEN's "Experimental & Research Center" has carried out more than 200 research programs, but also more than 650 Greek and international educational seminars. ELPEN's research efforts have borne great fruit: Elpenhaler®, an innovative inhaler device that was invented by ELPEN's Chairman and Founder, Mr. D. Pentafragas, is one example. Elpenhaler® has been approved in 27 European countries and holds international patents in more than 100 countries.
In the same time, ELPEN is actively engaged in Corporate Social Responsibility programs across Greece (with a particular focus on remote areas), but also overseas (e.g. the mission in Congo). ELPEN's CSR program supports five domains: Environment, Culture, Education, Sports and Charity, with a number of relevant activities for athletes, charitable organizations, socially vulnerable groups, cultural/environmental associations in peripheral regions, underprivileged valedictorian students, and children from multi-membered families.
The development of new products and markets has always been a strategic aim for ELPEN. Today, the company has an export activity for 30 products of high quality and therapeutic value, in 27 European countries, and in 60 worldwide. In parallel, through its continuous development of corporate social responsibility programs and its human-centered way of functioning, ELPEN promotes its Founder's vision: a vision no other than the constant contribution to our fellow-men.
During the first years of the 21thcentury, amongst Greek pharmaceutical industries, ELPEN distinguishes itself as the pioneer in sales within the domestic out patient market. Today, it ranks 6th within a market of more than 400, domestic and multinational, pharmaceutical companies.